These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 18408485

  • 1. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P.
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [Abstract] [Full Text] [Related]

  • 2. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
    Marckmann P.
    Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
    [Abstract] [Full Text] [Related]

  • 3. [Nephrogenic systemic fibrosis].
    Breitschaft A, Stahlmann R.
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [Abstract] [Full Text] [Related]

  • 4. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
    Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P.
    Scand J Urol Nephrol; 2007 Oct; 41(6):565-6. PubMed ID: 17934986
    [Abstract] [Full Text] [Related]

  • 5. [Nephrogenic systemic fibrosis].
    Cavallini L, Abaterusso C, Bedogna V, Pertica N, Loschiavo C, Lupo A.
    G Ital Nefrol; 2008 Oct; 25(1):14-20. PubMed ID: 18264914
    [Abstract] [Full Text] [Related]

  • 6. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [Abstract] [Full Text] [Related]

  • 7. Case-control study of gadodiamide-related nephrogenic systemic fibrosis.
    Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS.
    Nephrol Dial Transplant; 2007 Nov; 22(11):3174-8. PubMed ID: 17483196
    [Abstract] [Full Text] [Related]

  • 8. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS, Marckmann P.
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [Abstract] [Full Text] [Related]

  • 9. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.
    Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R.
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):258-63. PubMed ID: 17699422
    [Abstract] [Full Text] [Related]

  • 10. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD, Bernheisel CR.
    Am Fam Physician; 2009 Oct 01; 80(7):711-4. PubMed ID: 19817341
    [Abstract] [Full Text] [Related]

  • 11. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
    Rydahl C, Thomsen HS, Marckmann P.
    Invest Radiol; 2008 Feb 01; 43(2):141-4. PubMed ID: 18197066
    [Abstract] [Full Text] [Related]

  • 12. Update on nephrogenic systemic fibrosis.
    Thomsen HS, Marckmann P, Logager VB.
    Magn Reson Imaging Clin N Am; 2008 Nov 01; 16(4):551-60, vii. PubMed ID: 18926421
    [Abstract] [Full Text] [Related]

  • 13. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
    Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS.
    J Am Soc Nephrol; 2006 Sep 01; 17(9):2359-62. PubMed ID: 16885403
    [Abstract] [Full Text] [Related]

  • 14. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ.
    Invest Radiol; 2008 Jan 01; 43(1):65-75. PubMed ID: 18097279
    [Abstract] [Full Text] [Related]

  • 15. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).
    Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE.
    Invest Radiol; 2007 Feb 01; 42(2):139-45. PubMed ID: 17220732
    [Abstract] [Full Text] [Related]

  • 16. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M, Thuillier D, Lok C, Gras-Champel V.
    Therapie; 2007 Feb 01; 62(2):169-72. PubMed ID: 17582319
    [Abstract] [Full Text] [Related]

  • 17. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
    Heinrich M, Uder M.
    Rofo; 2007 Jun 01; 179(6):613-7. PubMed ID: 17497597
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR.
    Eur J Radiol; 2008 May 01; 66(2):230-4. PubMed ID: 18372138
    [Abstract] [Full Text] [Related]

  • 19. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
    Othersen JB, Maize JC, Woolson RF, Budisavljevic MN.
    Nephrol Dial Transplant; 2007 Nov 01; 22(11):3179-85. PubMed ID: 17890246
    [Abstract] [Full Text] [Related]

  • 20. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R.
    J Am Coll Cardiol; 2009 May 05; 53(18):1621-8. PubMed ID: 19406336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.